Nikang Therapeutics, Inc.

This early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so r…

This study tested two new drug combinations for people with advanced clear cell kidney cancer that had already been treated. The goal was to see if adding the experimental drug NKT2152 to standard therapies could shrink tumors or slow the disease. The trial was stopped early, so …

This trial tested an oral drug called NKT2152 for people with advanced clear cell kidney cancer that has worsened after other treatments. The drug works by blocking a protein that helps cancer grow. The study aimed to find the safest dose and see if it can shrink tumors or slow t…